Collaborators
Dr Gail Solomon, Reckitt-Benkiser, Parsippany, USA, Drug development, 2011 - 2013
Dr Keith Bunce, GlaxoSmithKline (UK)
Dr Thomas Leonard, GlaxoSmithKline (USA)
Dr Keith Foster, Health Protection Agency (Porton Down)
Dr Malcolm Johnson, GlaxoSmithKline (UK)
Dr Rupert Vessey, GlaxoSmithKline (USA)
Guest Lectures
Airway mucus hypersecretion: targeting intracellular mechanisms for pharmacotherapy, XXXIII Congreso Annual, Sociedad de Farmacologia de Chile, Olmue, V Region, Chile, 2011
Novel pharmacotherapeutic targets for asthma and COPD, Simposio Internacional, Facultad de Medicina, Instituto de Ciencias Biomedicas, Santiago, Chile, 2011
Small airways structure and function, Simposio Internacional, Facultad de Medicina, Instituto de Ciencias Biomedicas, Santiago, Chile, 2011
Airway mucus secretion and hypersecretion, Simposio Internacional, Facultad de Medicina, Instituto de Ciencias Biomedicas, Santiago, Chile, 2011
Airway mucus and mucin genes in COPD, Hot Issues in Chronic Obstructive Pulmonary Disease – Update. Chang Gung Memorial Hospital Medical School, Taipei, Taiwan, 2011
Future therapeutic targets for respiratory disease, 5th Annual Drug Delivery Systems, BSG Conference Centre, London, 2010
Muco-inhibitory drugs for airway mucus hypersecretion, International Society for Aerosols in Medicine, 17th Congress, Monterey, USA, 2009
Targets for the future, Academy of Pharmaceutical Sciences: ‘APS Inhalation 2009’, Nottingham Conference Centre, Nottingham, 2009
Mucoactive agents for mucus hypersecretory airway diseases, Gordon Research Conference: ‘Cilia, Mucus & Mucociliary Interactions’, Lucca, Italy, 2009
Inhibition of airway mucus hypersecretion: Botox for the lungs?, Respiratory Research Group Seminar Series 2009, Wythenshawe Hospital, University of Manchester, Manchester, 2009
Novel targets in mucus hypersecretion and modifying agents, COPD & Asthma: State of the Art, Management Forum, London, 2009
Re-targeted Botox for chronic bronchitis, Infection, Inflammation & Repair Seminar Series, University of Southampton, Southampton, 2009
Role of mucin in asthma pathogenesis, XXVIII Congress of the European Academy of Allergy and Clinical Immunology (EAACI 2009), Warsaw, Poland, 2009
New therapies to target MCC/CC in chronic bronchitis and asthma, ISAM/UNC Focus Symposium/ Workshop: ‘Mucociliary/Cough Clearance as a Biomarker for Therapeutic Development’, Research Triangle Park,, North Carolina, USA. ‘, 2008
Mucus hypersecretion and modifying agents, The Management of Chronic Obstructive Pulmonary Disease and Asthma, Management Forum, London, 2008
Inhibition of airway mucus hypersecretion, International Centre for Advanced Respiratory Medicine (CIMERA), Mallorca, Spain, 2008
Botox for the lungs?, Drug Delivery to the Lungs 19 (DDL19), The Aerosol Society, Edinburgh, Scotland, 2008
BoTox for the lungs?, Institute of Clinical Science, The Queen’s University of Belfast, Belfast, Northern Ireland, 2007
Physiology of mucus secretion, 39th Journal Respiratory Care Conference: ‘Airway Clearance: Physiology, Pharmacology, Techniques and Practice’, Cancun, Mexico, 2007
Function of goblet cells in mucus secretion, Gordon Research Conference: ‘Cilia, Mucus & Mucociliary Interactions’, Ventura Beach, California, USA, 2007
Retargeted botulinum endopeptidases inhibit airway mucus secretion: tox blocks snot, Biological Sciences Seminar Series, AstraZeneca, Lund, Sweden, 2007
Mucolytics and mucokinetics: acetylcysteine, Dornase, hyperosmolar aerosols and surfactant, 39th Journal Respiratory Care Conference: ‘Airway Clearance: Physiology, Pharmacology, Techniques and Practice’, Cancun, Mexico, 2007
Mucus hypersecretion and modifying agents, The Management of Chronic Obstructive Pulmonary Disease and Asthma, Management Forum, London, 2006
Inhibition of airway mucus secretion in asthm, XXV Congress of the European Academy of Allergology and Clinical Immunology (EAACI), Vienna, 2006
Mucus hypersecretion and modifying agents, COPD: Chronic Obstructive Pulmonary Disease, Management Forum, London, 2005
Airway mucus hypersecretion: rationales for pharmacotherapy, Second Shanghai International Symposium on Respiratory Diseases, Zhongshan Hospital, Fudan University, Shanghai, China, 2005
Mucus hypersecretion in COPD, Department of Academic Respiratory Medicine, St. Bartholomew’s Hospital, london, 2005
Botulism for the lungs: inhibition of airway mucus secretion, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, 2005
'Targeting mucus production in lung disease', British Thoracic Society Winter Meeting, London, 2004
'Airway mucus hypersecretio: basic mechanisms and rationales for novel therapy', Heatherwood and Wexham NHS Trust Medical half Day, Heatherwood Hospital, Ascot, 2004
'Mucus hypersecretion and modyfying agents', Annual Conference on COPD, Management Forum, London, 2004
'Airway mucus hypersecretion: new pharmacotherapy in asthma and COPD', The Rayne Institute, University College London, 2004
'Mucus regulation and treatment in asthma, COPD and allergic rhinitis', Asthma and Allergy Research group, NHLI, Imperial College London, 2004
'Airway mucus hypersecretion: models and pharmacotherapies', Oxagen Limited, Oxford, 2004
The Breathing Club: All Change in COPD: ' Mucus regulation and treatment', Chantilly, France, 2004
COPD: The Important Questions III: 'Mucoregulators', Marbella, Spain, 2004
Airway mucus hypersecretion: models and pharmacotherapeutics, Oxagen Limited, Oxford, 2004
Mucoregulators, COPD: The Important Questions III. Therapeutic Interventions Now and in the Future, Marbella, Spain, 2004
Mucus regulation and treatment, The Breathing Club: All Change in COPD, Chantilly, France, 2004
Airway mucus hypersecretion: new pharmacotherapy in asthma and COPD, Centre for Respiratory Research, The Rayne Institute, University College London, London, 2004
Mucus hypersecretion and modifying agents, Annual Conference on COPD, Management Forum, London, 2004
Airway mucus hypersecretion: basic mechanisms and rationales for novel therapy, Heatherwood and Wexham NHS Trust Medical Academic Half Day, Heatherwood Hospital, Ascot, 2004
Targeting mucus production in lung disease, British Thoracic Society, Winter Meeting, London, 2004
British Society for Allergy & Clinical Immunology: 'Neuronal Control of airway mucus secretion', East Midlands Conference Centre, Nottingham, UK, 2003
Neuronal control of airway mucus secretion, British Society for Allergy and Clinical Immunology, East Midlands Conference Centre, Nottingham, 2003
Airway mucus secretion: stimulation and rational approaches to inhibition of hypersecretion, Centre for Applied Microbiological Research, Porton Down, Wiltshire, 2003
Regulation of airway mucin secretion: stimulation and inhibition in experimental models and human disease, British Association for Lung Research Symposium on Airway Epithelial Defence Mechanisms, University of Brighton, 2003
6th Annual Conference on COPD: 'Mucus hypersecretion in COPD: pathophysiology and novel treatments', Management Forum, London, UK, 2003
British Association for Lung Research: 'Regulation of airway mucin secretion: stimulation and inhibition in expermental models and human disease', University of Brighton, UK, 2003
Airway mucus hypersecretion: basic mechanisms and novel pharmacotherapy (Molecular Biology of the Cell Forum), University of Sunderland, Sunderland, 2003
'Airway mucus secretion: stimulation and rational approaches to inhibition of hypersecretion', Centre for Applied Microbiological Research, Porton Down, Salisbury, 2003
'Airway mucus hypersecretion: basic mechanisms and novel pharmacotherapy', Molecular Biology of the Cell Forum, University of Sunderland, 2003
'Airway secretions', The Triangle of Asthma Management, Imperial College London, 2003
'Airway mucus hypersecretion: models and therapies', AstraZeneca, Charnwood, Loughborough, 2003
Mucus hypersecretion in COPD: pathophysiology and novel treatments, 6th Annual Conference on COPD, Management Forum, London, 2003
COPD 3, International Convention Centre. 'Mucus regulation.', Birmingham, UK, 2002
'Mucus hypersecretion in asthma and COPD: pathophysiology, models and treatment', Merck Frosst Canada, Quebec, Canada, 2002
2002 International Meeting of the Interest Group for Cilia, Mucus and Mucociliary Interactions, 'Airway mucus hypersecretion and considerations for rational novel therapy.', Miami Beach, USA, 2002
National Clinical Coding Conference. 'Mucous hypersecrtetion in asthma and COPD.', London, UK, 2002
'Airway mucosa: secretory cells, mucus and mucin genes', The XXth Congress of the European Acadamy of Allergology and Clinical Immunology, Berlin, Germany, 2001
'Mucin gene expression in airway inflammation', The Rayne Institute, University College London, 2001
Airway mucin gene expression: pathophysiology and models', Department of Cell and Molecular Biology, University of Lund, Sweden, 2001
'Mucus hypersecretion in asthma and COPD: pathophysiology and models', Roche Bioscience, Palo Alto, USA, 2001
Research Student Supervision
Madge,N, Effect of activated neutrophil products on small airway function
Sehra,G, Effect of diesel exhaust particals on airway inflammation